GHP Q2 2018

6 GHP / Q2 2018 , Most Innovative Regenerative Medicine Research Company - USA Axolotl Biologix is focused on science and research to uncover optimal enablement of the body’s own cells to create evidence-based clinical protocols. We profile the company to learn more about the unique work it undertakes in this vital area and how it works towards changing the health of the world’s population for the better while lowering patient costs. Since its inception in 2016, Axolotl Biologix’ mission has been to improve the quality of life for people around the world. Axolotl Biologix is committed to acting as an innovative leader of regenerative medicine through research, technology, and clinical application. Through science and research, the firm’s dedicated team is looking to create better products that physicians can use to provide better care for patients. To achieve this, the firm is committed to evidence-based protocols and collecting data on patient outcomes. As part of its commitment to changing lives for the better, Axolotl’s number one priority is patient safety, and as such the firm closely follow the U.S. Food and Drug Administration’s (FDA) Current Good Tissue Practices (CGTP) to meet and exceed standards. The firm has an established quality program with fully documented procedures and trained staff to ensure that at every stage of research, BI180023 manufacturing, and treatment, patients safety is first and foremost. Currently, the firm is generating revenue through three products, and as has two exclusive, worldwide licenses to two U.S. patents using Tropoelastin in medical applications. The first product using Tropoelastin that is under current development is an extracellular matrix (ECM). The next three products using the biomaterial is a surgical mesh, a cardiac patch, and an electrospun blood vessel that has elasticity and tensile strength. Elastin is the structural protein that provides tissues with their ability to stretch and recoil and is most prevalent, and essential, in organs that expand and contract. Elastin in its hydrolyzed form has been made available historically when isolated from animals, but the resulting inert material has little value for engineered tissue applications. Tropoelastin is the natural high molecular weight (70kDA) precursor to elastin. Research